#AHA20 – In patients hospitalized for heart failure with iron deficiency, intravenous Ferric carboxymaltose at discharge reduced the risk of heart failure rehospitalizations

Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial – The Lancet

Commentaries: Intravenous iron reduced rehospitalization risk in people with heart failure – American Heart Association AND AFFIRM-AHF: IV Iron Supplementation Linked to Fewer Repeat Hospitalizations for HF – TCTMD

Commentary on Twitter

Latebreaker at #AHA20 @AHAMeetings—Ferric carboxymaltose for iron deficiency at discharge after acute #heartfailure: AFFIRM-AHF, a multicentre, double-blind, randomised, controlled trial https://t.co/gRKtbsxfba pic.twitter.com/k67HDJMW2b

— The Lancet (@TheLancet) November 14, 2020